Predictive Accuracy of Markers or Risk Scores for Interval Censored Survival Data
Yuan Wu(Shanghai Medical College of Fudan University), Kouros Owzar(Duke University), Jiaxing Lin(Duke University), Beilin Jia(University of North Carolina at Chapel Hill), Xiaofei Wang(NCR (United States))
Cited by 3
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655